The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: A systematic review and meta-analysis

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1077-1088

  Stuijver, Danka J F ^a,b   van Zaane, Bregje ^a,b   Romualdi, Erica ^c   Brandjes, Dees P M ^a,b   Gerdes, Victor E A ^a,b   Squizzato, Alessandro ^c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Coagulation; Fibrinolysis; Hyperthyroidism; Thyrotoxicosis

Indexed keywords

ANTITHYROID AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; CARBIMAZOLE; FIBRINOGEN; FIBRINOLYTIC FACTOR; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THYROID HORMONE; VON WILLEBRAND FACTOR;

HEMOSTASIS; HUMAN; HYPERTHYROIDISM; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THYROTOXICOSIS; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; FIBRINOLYSIS; HUMANS; HYPERTHYROIDISM; RISK FACTORS; THROMBOSIS; THYROTOXICOSIS;

EID: 84870885768     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-07-0496     Document Type: Review

References (58)

1. Squizzato A, Romualdi E, Buller HR, et al. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-2420.
2. Vescovi P P, Favaloro EJ, Lippi G, et al. The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost 2011; 37: 7-10.
3. Arnaout MA, Awidi AS, el-Najdawi AM, et al. Arginine-vasopressin and endothe-lium-associated proteins in thyroid disease. Acta Endocrinol 1992; 126: 399-403.
4. Dorr M, Robinson DM, Wallaschofski H, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 2006; 91: 530-534.
5. Erem C, Ersoz HO, Karti SS, et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002; 25: 345-350.
6. Li Y, Chen H, Tan J, et al. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity. Eur J Clin Invest 1998; 28: 1050-1054.
7. Lippi G, Franchini M, Targher G, et al. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. J Thromb Thrombolysis 2009; 28: 362-365.
8. Ozcan MA, Comlekci A, Demirkan F, et al. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. Thromb Res 2003; 110: 243-247.
9. van Zaane B, Squizzato A, Debeij J, et al. Alterations in coagulation and fibrinoly-sis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. J Thromb Haemost 2011; 9: 1816-1824.
10. van Tulder MW, Assendelft WJ, Koes BW, et al. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997; 22: 2323-2330.
11. Verhagen A P, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235-1241.
12. Wells G, Shea B, O'Connell D, et al. Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. 2011. Available at: http://www.ohrica/programs/clnical_epidemiology/oxford.asp.
13. Higgins J P, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available at: http://www.cochrane-handbook.org. Wiley, Oxford UK.
14. Lipsey MW, Wilson DB. Procedures for computing effect sizes values from eligible study reports. Practical meta-analysis. Sage Publications Ltd; 2000; pp. 172-206.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
17. Burggraaf J, Lalezari S, Emeis JJ, et al. Endo thel ial function in p atients w ith hy per-thyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001; 11: 153-160.
18. Coban E, Aydemir M, Yazicioglu G, et al. Endothelial dysfunction in subjects with subclinical hyperthyroidism. J Endocrinol Invest 2006; 29: 197-200.
19. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf) 2006; 64: 323-329.
20. Graninger W, Pirich KR, Speiser W, et al. Effect of thyroid hormones on plasma protein concentrations in man. J Clin Endocrinol Metab 1986; 63: 407-411.
21. Liu L, Wang X, Lin Z, et al. Elevated plasma levels of VWF:Ag in hyperthyroidism are mediated through beta-adrenergic receptors. Endocr Res 1993; 19: 123-133.
22. Marongiu F, Conti M, Mameli G, et al. Fibrinogen and fibrinolytic activity in hy-perthyroidism before and after antithyroid treatment. J Endocrinol Invest 1988; 11: 723-725.
23. Marongiu F, Conti M, Murtas ML, et al. Activation of blood coagulation and fibri-nolysis in Graves' disease. Horm Metab Res 1991; 23: 609-611.
24. Marongiu F, Conti M, Murtas ML, et al. Anticardiolipin antibodies in Grave's disease: relationship with thrombin activity in vivo. Thromb Res 1991; 64: 745-749.
25. Morishita E, Hashimoto T, Asakura H, et al. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease. Thromb Haemost 1998; 79: 919-923.
26. Myrup B, Bregengard C, Faber J. Primary haemostasis in thyroid disease. J Intern Med 1995; 238: 59-63.
27. Rogers JS, Shane SR, Jencks FS. Factor VIII activity and thyroid function. Ann Intern Med 1982; 97: 713-716.
28. Rosc D, Zastawna E, Drewniak W, et al. Plasminogen activators (tissue type t-PA, urokinase type u-PA) and plasminogen activators inhibitors (PAI-1) in Graves disease. Med Sci Monit 1998; 4: 975-978.
29. Wahrenberg H, Wennlund A, Hoffstedt J. Increased adipose tissue secretion of in-terleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism. Eur J Endocrinol 2002; 146: 607-611.
30. Mousa SS, Davis FB, Davis PJ, et al. Human platelet aggregation and degranu-lation is induced in vitro by L-thyroxine, but not by 3,5,3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA). Clin Appl Thromb Hemost 2010; 16: 288-293.
31. Olukman O, Sahin U, Kavakli T, et al. Investigation of acquired von Willebrand Syndrome in children with hypothyroidism: reversal after treatment with thyr-oxine. J Pediatr Endocrinol Metab 2010; 23: 967-974.
32. Yong PH, Junit SM, Harun F, et al. Patients with congenital hypothyroidism demonstrate different altered expression of plasma fibrinogen and haptoglobin poly-peptide chains. Clin Biochem 2006; 39: 126-132.
33. Nowicki TS, Moscatello AL, Shin E, et al. The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target. J Clin Endocrinol Metab 2011; 96: 3062-3064.
34. Reinke CE, Hadler RA, Karakousis GC, et al. Does the presence of thyroid cancer increase the risk of venous thromboembolism in patients undergoing thyroidec-tomy? Surgery 2011; 150: 1275-1285.
35. Ulisse S, Baldini E, Sorrenti S, et al. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab 2011; 96: 504-508.
36. Akinci B, Comlekci A, Yener S, et al. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients. Endocr J 2007; 54: 593-599.
37. Akinci B, Demir T, Comlekci A, et al. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules. Med Princ Pract 2011; 20: 23-28.
38. Brona A, Bohdanowicz-Pawlak A, Jedrzejuk D, et al. Fibrinogen and D-dimers levels in patients with hyperthyroidism before and after radioiodine therapy. En-dokrynol Pol 2011; 62: 409-415.
39. Coban E, Aydemir M. Levels of plasma fibrinogen and D-dimer in subjects with subclinical hyperthyroidism. Med Sci Monit 2008; 14: CR42-CR46.
40. Demir T, Akinci B, Comlekci A, et al. Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation. Clin Endocrinol 2009; 71: 446-450.
41. Erem C, Ucuncu O, Yilmaz M, et al. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthy-roidism. Endocrine 2009; 36: 473-478.
42. Homoncik M, Gessl A, Ferlitsch A, et al. Altered platelet plug formation in hyper-thyroidism and hypothyroidism. J Clin Endocrinol Metab 2007; 92: 3006-3012.
43. Mohamed-Ali MS, Ahmed RO. Coagulation profiles in hypothyroid and hyper-thyroid female patients in Sudan. Saudi Med J 2008; 29: 1289-1293.
44. Rogers JS, Shane SR. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983; 102: 444-449.
45. Franchini M, Lippi G, Manzato F, et al. Thyroid-associated autoimmune coagulation disorders. J Thromb Thrombolysis 2010; 29: 87-91.
46. Hoylaerts MF, Thys C, Arnout J, et al. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. Blood 1998; 91: 2810-2817.
47. Niessen RW, Pfaffendorf BA, Sturk A, et al. The influence of insulin, beta-estra-diol, dexamethasone and thyroid hormone on the secretion of coagulant and anticoagulant proteins by HepG2 cells. Thromb Haemost 1995; 74: 686-692.
48. Shih CH, Chen SL, Yen CC, et al. Thyroid hormone receptor-dependent tran-scriptional regulation of fibrinogen and coagulation proteins. Endocrinology 2004; 145: 2804-2814.
49. Paggi A, Caccavo D, Ferri GM, et al. Anti-cardiolipin antibodies in autoimmune thyroid diseases. Clin Endocrinol 1994; 40: 329-333.
50. Thomas D P, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-644.
51. Danescu LG, Badshah A, Danescu SC, et al. Venous thromboembolism in patients hospitalized with thyroid dysfunction. Clin Appl Thromb Hemost 2009; 15: 676-680.
52. Debeij J, Dekkers O, Asvold B, et al. Increased levels of free thyroxine and risk of venous thrombosis in a large population-based prospective study. J Thromb Hae-most 2012; 10: 1539-1546.
53. Kootte RS, Stuijver DJ, Dekkers OM, et al. The incidence of venous thromboem-bolism in patients with overt hyperthyroidism: A retrospective multicentre cohort study. Thromb Haemost 2012; 107: 417-422.
54. Lin HC, Yang LY, Kang JH. Increased risk of pulmonary embolism among patients with hyperthyroidism: A 5-year follow-up study. J Thromb Haemost 2010; 8: 2176-2181.
55. Ramagopalan S V, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: Record-linkage study. BMC Med 2011; 9: 1.
56. van Zaane B, Squizzato A, Huijgen R, et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: A case-control study. Blood 2010; 115: 4344-4349.
57. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonar y e mbolism in patients with autoimmune disorders: A nationwide follow-up study from Sweden. Lancet 2012; 379: 244-249. 58.
58. Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review. Clin Appl Thromb Hemost 2011; 17: 387-392.